Drugs / XC243
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05628116 | Sep 2022 → Sep 2023 | — | PHARMENTERPRISES LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06391164 | Apr 2024 → Dec 2025 | cystitis | PHARMENTERPRISES LLC | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XC243 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05628116 ↗ |
| Route | Oral | “after single and multiple oral administration” NCT05628116 ↗ |